*The House Clinic; †University of Southern California Keck School of Medicine, Los Angeles; and ‡Research Consultant to House Research Institute, Marina del Rey, California, U.S.A.
Otol Neurotol. 2013 Oct;34(8):1456-64. doi: 10.1097/MAO.0b013e3182976552.
To determine whether partial tumor removal in large vestibular schwannoma improves facial nerve outcomes while maintaining a low risk of tumor regrowth/recurrence.
Retrospective chart review and prospective database.
Tertiary neurotologic referral center.
Four hundred patients with a vestibular schwannoma of 2.5 cm or greater in maximum diameter undergoing translabyrinthine microsurgical resection from 2001 to 2011. There were 325 gross total resections (GTR), 44 near total resections (NTR), and 31 subtotal resections (STR), with an overall mean tumor size of 3.2 cm (standard deviation, 0.7).
INTERVENTION(S): Translabyrinthine surgical tumor resection.
House-Brackmann (H-B) facial nerve grade postoperatively and at 1 year, tumor regrowth/recurrence (≥2 mm), additional treatment, and complications.
Higher rates of H-B facial nerve Grades I and II were achieved at both the postoperative and 1-year follow-ups in the NTR (78%, 97%) and STR (71%, 96%) groups compared with GTR (53%, 77%) (p ≤ 0.001). Eye treatment, medical or surgical, was required more often in GTR (28.0%) than NTR and STR (8% and 21%, respectively, p ≤ 0.04), with no other differences in complications. The NTR and STR groups had a significantly higher rate of regrowth than GTR resection (21% and 22% versus 3%) (p ≤ 0.001) at average follow-up times of 3.7, 3.7, and 5.1 years, respectively, and need for further treatment occurred at a higher rate, although infrequently, in NTR and STR (2% and 10% versus 0%) (p ≤ 0.001).
Near total and subtotal removal in large tumors are viable treatment options to maintain facial nerve function. During the follow-up period examined in this study, there was a low risk of need for further treatment. Longer-term follow-up is needed to better assess the need for retreatment in patients treated with NTR and STR.
确定大型前庭神经鞘瘤的部分肿瘤切除是否能改善面神经结果,同时降低肿瘤复发/再生长的风险。
回顾性图表回顾和前瞻性数据库。
三级神经耳科转诊中心。
2001 年至 2011 年期间,400 名最大直径为 2.5 厘米或更大的前庭神经鞘瘤患者接受经迷路显微手术切除。其中 325 例为全切除(GTR),44 例为近全切除(NTR),31 例为次全切除(STR),肿瘤平均大小为 3.2 厘米(标准差 0.7)。
经迷路手术肿瘤切除。
术后和 1 年时的 House-Brackmann(H-B)面神经分级、肿瘤复发/再生长(≥2 毫米)、额外治疗和并发症。
NTR(78%,97%)和 STR(71%,96%)组在术后和 1 年随访时获得 H-B 面神经分级 I 和 II 的比例均高于 GTR 组(53%,77%)(p≤0.001)。GTR(28.0%)比 NTR 和 STR(分别为 8%和 21%,p≤0.04)更常需要眼部治疗,包括药物或手术治疗,且无其他并发症差异。NTR 和 STR 组的再生长率明显高于 GTR 切除组(21%和 22%比 3%)(p≤0.001),平均随访时间分别为 3.7、3.7 和 5.1 年,NTR 和 STR 组进一步治疗的发生率虽然较低,但也较高(2%和 10%比 0%)(p≤0.001)。
在大型肿瘤中进行近全切除和次全切除是维持面神经功能的可行治疗选择。在本研究的随访期间,进一步治疗的风险较低。需要更长时间的随访,以更好地评估 NTR 和 STR 治疗患者的再次治疗需求。